Laboratory Medicine ›› 2024, Vol. 39 ›› Issue (10): 956-962.DOI: 10.3969/j.issn.1673-8640.2024.10.006
Previous Articles Next Articles
LEI Ming, ZHAI Li, WEI Ying, LIN Yichen, GUO Mengyue()
Received:
2023-12-25
Revised:
2024-06-03
Online:
2024-10-30
Published:
2024-11-08
CLC Number:
LEI Ming, ZHAI Li, WEI Ying, LIN Yichen, GUO Mengyue. Application of nomogram model based on clinical characteristics and serum tumor markers in differential diagnosis of benign and malignant lung lesions[J]. Laboratory Medicine, 2024, 39(10): 956-962.
Add to citation manager EndNote|Ris|BibTeX
URL: https://www.shjyyx.com/EN/10.3969/j.issn.1673-8640.2024.10.006
组别 | 例数 | 年龄/岁 | 性别 | 吸烟史/ [例(%)] | 家族肿瘤史/ [例(%)] | |
---|---|---|---|---|---|---|
男/[例(%)] | 女/[例(%)] | |||||
良性结节组 | 164 | 52.23 ±11.71 | 96(58.5) | 68(41.5) | 66(40.2) | 6(3.7) |
肺癌组 | 935 | 57.14±10.02 | 633(67.7) | 302(32.3) | 460(49.2) | 91(9.7) |
统计值 | 5.63 | 5.26 | 4.49 | 6.52 | ||
P值 | <0.001 | 0.022 | 0.034 | 0.011 | ||
组别 | CEA/(ng·mL-1) | CA125/(U·mL-1) | CA15-3/(U·mL-1) | CA19-9/(U·mL-1) | CA242/(U·mL-1) | |
良性结节组 | 1.99(1.18,3.01) | 15.77(10.21,28.17) | 11.41(8.45,17.90) | 10.11(5.92,14.87) | 6.02(3.66,10.25) | |
肺癌组 | 3.63(2.06,6.62) | 18.60(11.87,34.09) | 14.18(10.29,20.75) | 11.70(6.86,20.33) | 6.31(3.33,13.15) | |
统计值 | 8.76 | 2.70 | 4.63 | 2.77 | 0.77 | |
P值 | <0.001 | 0.007 | <0.001 | 0.006 | 0.443 | |
组别 | CA72-4/ (U·mL-1) | CYFRA21-1/(ng·mL-1) | FER/(μg·L-1) | SCC-Ag/(μg·L-1) | NSE/(ng·mL-1) | |
良性结节组 | 2.50(1.46,4.98) | 2.10(1.64,2.99) | 267.90(133.90,531.40) | 0.65(0.38,0.91) | 11.44(9.87,13.58) | |
肺癌组 | 2.89(1.49,6.38) | 3.37(2.27,6.16) | 298.35(160.60,525.80) | 0.76(0.49,1.12) | 12.71(10.82,15.77) | |
统计值 | 1.63 | 10.87 | 1.07 | 4.13 | 5.70 | |
P值 | 0.104 | <0.001 | 0.284 | <0.001 | <0.001 |
组别 | 例数 | 年龄/岁 | 性别 | 吸烟史/ [例(%)] | 家族肿瘤史/ [例(%)] | |
---|---|---|---|---|---|---|
男/[例(%)] | 女/[例(%)] | |||||
良性结节组 | 164 | 52.23 ±11.71 | 96(58.5) | 68(41.5) | 66(40.2) | 6(3.7) |
肺癌组 | 935 | 57.14±10.02 | 633(67.7) | 302(32.3) | 460(49.2) | 91(9.7) |
统计值 | 5.63 | 5.26 | 4.49 | 6.52 | ||
P值 | <0.001 | 0.022 | 0.034 | 0.011 | ||
组别 | CEA/(ng·mL-1) | CA125/(U·mL-1) | CA15-3/(U·mL-1) | CA19-9/(U·mL-1) | CA242/(U·mL-1) | |
良性结节组 | 1.99(1.18,3.01) | 15.77(10.21,28.17) | 11.41(8.45,17.90) | 10.11(5.92,14.87) | 6.02(3.66,10.25) | |
肺癌组 | 3.63(2.06,6.62) | 18.60(11.87,34.09) | 14.18(10.29,20.75) | 11.70(6.86,20.33) | 6.31(3.33,13.15) | |
统计值 | 8.76 | 2.70 | 4.63 | 2.77 | 0.77 | |
P值 | <0.001 | 0.007 | <0.001 | 0.006 | 0.443 | |
组别 | CA72-4/ (U·mL-1) | CYFRA21-1/(ng·mL-1) | FER/(μg·L-1) | SCC-Ag/(μg·L-1) | NSE/(ng·mL-1) | |
良性结节组 | 2.50(1.46,4.98) | 2.10(1.64,2.99) | 267.90(133.90,531.40) | 0.65(0.38,0.91) | 11.44(9.87,13.58) | |
肺癌组 | 2.89(1.49,6.38) | 3.37(2.27,6.16) | 298.35(160.60,525.80) | 0.76(0.49,1.12) | 12.71(10.82,15.77) | |
统计值 | 1.63 | 10.87 | 1.07 | 4.13 | 5.70 | |
P值 | 0.104 | <0.001 | 0.284 | <0.001 | <0.001 |
项目 | 单因素分析 | 多因素分析 | |||
---|---|---|---|---|---|
OR值(95%CI) | P值 | OR值(95%CI) | P值 | ||
年龄 | 1.042(1.026~1.059) | <0.001 | 1.019(1.001~1.037) | 0.038 | |
性别(男与女) | 0.674(0.480~0.946) | 0.023 | 1.311(0.774~2.220) | 0.313 | |
吸烟史(无与有) | 1.438(1.026~2.015) | 0.035 | 1.083(0.648~1.809) | 0.761 | |
家族肿瘤史(无与有) | 2.839(1.222~6.599) | 0.015 | 3.243(1.357~7.749) | 0.008 | |
CEA | 1.462(1.309~1.634) | <0.001 | 1.374(1.225~1.540) | <0.001 | |
CA125 | 1.006(1.001~1.011) | 0.026 | 0.997(0.992~1.002) | 0.219 | |
CA15-3 | 1.044(1.020~1.070) | <0.001 | 1.022(0.997~1.048) | 0.090 | |
CA19-9 | 1.000(1.000~1.001) | 0.714 | |||
CA242 | 1.004(0.998~1.010) | 0.230 | |||
CA72-4 | 1.019(0.998~1.040) | 0.070 | |||
CYFRA21-1 | 1.401(1.251~1.570) | <0.001 | 1.262(1.127~1.412) | <0.001 | |
FER | 1.000(1.000~1.001) | 0.149 | |||
SCC-Ag | 1.592(1.185~2.139) | 0.002 | 1.033(0.754~1.415) | 0.841 | |
NSE | 1.099(1.049~1.150) | <0.001 | 1.073(1.024~1.125) | 0.003 |
项目 | 单因素分析 | 多因素分析 | |||
---|---|---|---|---|---|
OR值(95%CI) | P值 | OR值(95%CI) | P值 | ||
年龄 | 1.042(1.026~1.059) | <0.001 | 1.019(1.001~1.037) | 0.038 | |
性别(男与女) | 0.674(0.480~0.946) | 0.023 | 1.311(0.774~2.220) | 0.313 | |
吸烟史(无与有) | 1.438(1.026~2.015) | 0.035 | 1.083(0.648~1.809) | 0.761 | |
家族肿瘤史(无与有) | 2.839(1.222~6.599) | 0.015 | 3.243(1.357~7.749) | 0.008 | |
CEA | 1.462(1.309~1.634) | <0.001 | 1.374(1.225~1.540) | <0.001 | |
CA125 | 1.006(1.001~1.011) | 0.026 | 0.997(0.992~1.002) | 0.219 | |
CA15-3 | 1.044(1.020~1.070) | <0.001 | 1.022(0.997~1.048) | 0.090 | |
CA19-9 | 1.000(1.000~1.001) | 0.714 | |||
CA242 | 1.004(0.998~1.010) | 0.230 | |||
CA72-4 | 1.019(0.998~1.040) | 0.070 | |||
CYFRA21-1 | 1.401(1.251~1.570) | <0.001 | 1.262(1.127~1.412) | <0.001 | |
FER | 1.000(1.000~1.001) | 0.149 | |||
SCC-Ag | 1.592(1.185~2.139) | 0.002 | 1.033(0.754~1.415) | 0.841 | |
NSE | 1.099(1.049~1.150) | <0.001 | 1.073(1.024~1.125) | 0.003 |
[1] | RYŠKA A. Molecular pathology in real time[J]. Cancer Metastasis Rev, 2016, 35(1):129-140. |
[2] |
CHEUNG W K, NGUYEN D X. Lineage factors and differentiation states in lung cancer progression[J]. Oncogene, 2015, 34(47):5771-5780.
DOI PMID |
[3] |
WANG D C, WANG X. Tomorrow's genome medicine in lung cancer[J]. Semin Cancer Biol, 2017, 42:39-43.
DOI PMID |
[4] |
DE SOUSA V M L, CARVALHO L. Heterogeneity in lung cancer[J]. Pathobiology, 2018, 85(1-2):96-107.
DOI PMID |
[5] | ZITO MARINO F, BIANCO R, ACCARDO M, et al. Molecular heterogeneity in lung cancer:from mechanisms of origin to clinical implications[J]. Int J Med Sci, 2019, 16(7):981-989. |
[6] | 杨安妮, 黎泳娥, 洪荣臻. DCE-MRI联合CA125、CA153对肺部良恶性肿块/结节鉴别效能及意义[J]. 中国CT和MRI杂志, 2022, 20(5):57-60. |
[7] | BALACHANDRAN V P, GONEN M, SMITH J J, et al. Nomograms in oncology:more than meets the eye[J]. Lancet Oncol, 2015, 16(4):e173-e180. |
[8] | ZWEIG M H, CAMPBELL G. Receiver-operating characteristic(ROC)plots:a fundamental evaluation tool in clinical medicine[J]. Clin Chem, 1993, 39(4):561-577. |
[9] | SUNG H, FERLAY J, SIEGEL R L, et al. Global Cancer Statistics 2020:GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J]. CA Cancer J Clin, 2021, 71(3):209-249. |
[10] | CHEN F, LI J, QI X, et al. Diagnostic value of CYFRA 21-1 and carcinoembryonic antigen in diagnosis of operable lung cancer from benign lung disease[J]. J Cancer Res Ther, 2018, 14(Suppl):S400-S404. |
[11] | WU H, WANG Q, LIU Q, et al. The serum tumor markers in combination for clinical diagnosis of lung cancer[J]. Clin Lab, 2020, 66(3). |
[12] |
张海晨, 王浩, 宋云霄, 等. 多项肿瘤标志物联合检测模型在肺癌诊断中的应用价值[J]. 检验医学, 2018, 33(7):590-596.
DOI |
[13] |
张丽英, 傅冠华, 吴俊琪. 4项血清肿瘤标志物在肺癌辅助诊断和疗效评估中的价值[J]. 检验医学, 2019, 34(4):331-334.
DOI |
[14] |
LI Y, CAO H, JIAO Z, et al. Carcinoembryonic antigen interacts with TGF-{beta} receptor and inhibits TGF-{beta} signaling in colorectal cancers[J]. Cancer Res, 2010, 70(20):8159-8168.
DOI PMID |
[15] | ZHANG Z H, HAN Y W, LIANG H, et al. Prognostic value of serum CYFRA21-1 and CEA for non-small-cell lung cancer[J]. Cancer Med, 2015, 4(11):1633-1638. |
[16] | TAKADA M, MASUDA N, MATSUURA E, et al. Measurement of cytokeratin 19 fragments as a marker of lung cancer by CYFRA 21-1 enzyme immunoassay[J]. Br J Cancer, 1995, 71(1):160-165. |
[17] | GARCIA-VALDECASAS GAYO S, RUIZ-ALVAREZ M J, GONZALEZ-GAY D, et al. CYFRA 21-1 in patients with suspected cancer:evaluation of an optimal cutoff to assess the diagnostic efficacy and prognostic value[J]. Adv Lab Med, 2020, 1(4):20200005. |
[18] |
GENET S A A M, VISSER E, VAN DEN BORNE B E E M, et al. Correction of the NSE concentration in hemolyzed serum samples improves its diagnostic accuracy in small-cell lung cancer[J]. Oncotarget, 2020, 11(27):2660-2668.
DOI PMID |
[19] | MOLINA R, MARRADES R M, AUGÉ J M, et al. Assessment of a combined panel of six serum tumor markers for lung cancer[J]. Am J Respir Crit Care Med, 2016, 193(4):427-437. |
[1] | WANG Yafei, ZHANG Zhenjun, SONG Changliang, YANG Qiong. Roles of Notch1 mRNA and Dickkopf-1 in assessing the therapeutic responsiveness of pembrolizumab in non-small cell lung cancer patients [J]. Laboratory Medicine, 2024, 39(7): 627-633. |
[2] | ZHANG Miaomiao, DUAN Dongkui, YU Chun, WANG Lina. Expression and prognostic assessment value of miR-924 and SLC1A5 in lung cancer tissues [J]. Laboratory Medicine, 2024, 39(1): 13-18. |
[3] | ZHOU Yunlan, SHEN Lisong. Clinical application and challenges of liquid biopsy biomarkers in non-small cell lung cancer [J]. Laboratory Medicine, 2023, 38(9): 807-811. |
[4] | CHEN Ying, LI Wei, LIN Tao, YANG Li. Relationship between PFTK1 expression level and microvessel density and postoperative prognosis in non-small cell lung cancer [J]. Laboratory Medicine, 2023, 38(7): 634-639. |
[5] | YANG Zhongxin, LI Xiaoyu, CHEN Tao, CAO Wenjun. Roles of IL-8 and MMP-2 in the prognosis of non-small cell lung cancer patients after thoracoscopic segmentectomy [J]. Laboratory Medicine, 2023, 38(4): 342-346. |
[6] | SONG Shiwei, LI Jingwu, LIN Tao, LIU Zeyu, WANG Zhiqiang, SUN Weidong. Relationship between GPNMB and non-small cell lung cancer immune infiltration and prognosis [J]. Laboratory Medicine, 2023, 38(4): 347-351. |
[7] | LIU Xingqiang, NING Lifen, LI Lin, CHEN Zhongcheng. Correlation of lung cancer clinicopathological characteristics with FR+-CTC,ANXA2 and ProGRP [J]. Laboratory Medicine, 2022, 37(8): 735-740. |
[8] | GAO Feng. Research progress of new tumor molecular markers in the age of precision medicine:from accurate diagnosis to precision chemotherapy [J]. Laboratory Medicine, 2022, 37(4): 309-312. |
[9] | ZHAO Mingna, ZHANG Chenzi, HONG Qiushuang, LOU Jiatao. Mechanism of IL-8/miR-182 positive feedback regulatory axis in non-small cell lung cancer [J]. Laboratory Medicine, 2022, 37(4): 349-355. |
[10] | WANG Jianying, WANG Shanshan, ZHU Jun, HUANG Xiaochun, WAN Yuxiang, LIU Yun. Distribution and drug resistance of respiratory infection pathogens in patients with lung cancer after chemotherapy [J]. Laboratory Medicine, 2022, 37(4): 356-359. |
[11] | XU Runhao, ZOU Chen, CAO Yun, CHEN Feng, LIU Yijing, ZHANG Shulin, ZHANG Jie. Roles of serum amino acid determinations in the diagnosis of early non-small-cell lung cancer [J]. Laboratory Medicine, 2022, 37(12): 1157-1163. |
[12] | XIONG Zhongbo, WANG Lei, YIN Beiqi, DAI Yue, WEI Xiaoqing, LU Pei. Clinical roles of SAA and CRP in pathological staging and metastasis of gastrointestinal cancer [J]. Laboratory Medicine, 2022, 37(1): 51-55. |
[13] | MAN Xianfeng, HE Xiaoting, ZHANG Ying, YU Weiwei, WANG Qi, YIN Hanwei, WANG Runjie. Application of thioredoxin reductase in monitoring the curative effect of lung cancer [J]. Laboratory Medicine, 2022, 37(1): 56-59. |
[14] | XU Runhao, ZOU Chen, ZHANG Jie, LI Min, ZHANG Shulin. Application of serum bile acid spectrum in the differential diagnosis of pneumonia and lung cancer [J]. Laboratory Medicine, 2021, 36(1): 1-7. |
[15] | PENG Jiaowu, SUN Chengmou. Diagnostic value of miR-124a and miR-449a in plasma of non-small cell lung cancer [J]. Laboratory Medicine, 2021, 36(1): 34-38. |
Viewed | ||||||
Full text |
|
|||||
Abstract |
|
|||||